Today's News |
Aequus Receives Approval for Short Form Base Shelf Prospectus to Raise up to $20 Million
Tuesday, August 22, 2017Company Profile | Follow Company
Vancouver, BC, August 22, 2017--(T-Net)--Aequus Pharmaceuticals Inc. (TSX-V: AQS), a specialty pharmaceutical company with a focus on developing, advancing and promoting differentiated products, announced that it has received a receipt for its final short form base shelf prospectus.
The Prospectus will allow Aequus to offer up to C$20,000,000 of common shares, preferred shares, debt securities, subscription receipts, units and warrants from time to time, in each of British Columbia, Alberta, Saskatchewan, Manitoba and Ontario, until the Prospectus expires on September 16, 2019.
This new filing replaces the Company's existing base shelf prospectus, which expired on August 6, 2017.
This shelf prospectus is intended to give Aequus the flexibility to take advantage of financing opportunities when market conditions are favourable.
About Aequus
Aequus Pharmaceuticals Inc. (TSX-V: AQS, OTCQB: AQSZF) is a growing specialty pharmaceutical company focused on developing and commercializing high quality, differentiated products. Aequus' development stage pipeline includes several products in neurology and psychiatry with a goal of addressing the need for improved medication adherence through enhanced delivery systems. Aequus intends to commercialize its internal programs in Canada alongside its current portfolio of marketed established medicines and will look to form strategic partnerships that would maximize the reach of its product candidates worldwide. Aequus plans to build on its Canadian commercial platform through the launch of additional products that are either created internally or brought in through an acquisition or license; remaining focused on highly specialized therapeutic areas. For further information, please visit www.aequuspharma.ca.
Contact Information:
Aequus Investor Relations
Email: investors@aequuspharma.ca
Phone: 604-336-7906
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Other Recent Company News |
|||||||||||||||||||
|